Asia-Pacific Insulin Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Asia-Pacific Insulin Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Asia-Pacific Insulin Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Increase in diabetes prevalence
5.1.2 Growth in demand for insulin therapies

5.2 Market Opportunities

5.2.1 Expansion in diabetes management market
5.2.2 Growth in insulin pen and pump usage

5.3 Future Trends

5.3.1 Increasing adoption of insulin pumps and pens
5.3.2 Development of insulin biosimilars and new delivery technologies

5.4 Impact of Drivers and Restraints

6. Asia-Pacific Insulin Market Regional Analysis

6.1 Asia-Pacific Insulin Market Overview

6.2 Asia-Pacific Insulin Market Revenue 2020-2028 (US$ Million)

6.3 Asia-Pacific Insulin Market Forecast Analysis

7. Asia-Pacific Insulin Market Analysis – by Type

7.1 Long Acting Insulin

7.1.1 Overview
7.1.2 Long Acting Insulin: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Rapid Acting Insulins

7.2.1 Overview
7.2.2 Rapid Acting Insulins: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Short acting Insulins and Traditional Human Insulins

7.3.1 Overview
7.3.2 Short acting Insulins and Traditional Human Insulins: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Concentrated Insulins and Combination Insulins

7.4.1 Overview
7.4.2 Concentrated Insulins and Combination Insulins: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Biosimilar Insulins

7.5.1 Overview
7.5.2 Biosimilar Insulins: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.6 Glucagon-like peptide-1

7.6.1 Overview
7.6.2 Glucagon-like peptide-1: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

7.7 Pens and Needles

7.7.1 Overview
7.7.2 Pens and Needles: Asia-Pacific Insulin Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia-Pacific Insulin Market – Asia-Pacific Analysis

8.1 Asia-Pacific

8.1.1 Asia-Pacific Insulin Market Breakdown, by Key Country, 2023 and 2028 (%)
8.1.1.1 Asia-Pacific Insulin Market – Revenue and Forecast Analysis – by Country
8.1.1.1 China: Asia-Pacific Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.1.1.1.1 China: Asia-Pacific Insulin Market Breakdown, by Type

8.1.1.2 India: Asia-Pacific Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.1.1.2.1 India: Asia-Pacific Insulin Market Breakdown, by Type

8.1.1.3 Japan: Asia-Pacific Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.1.1.3.1 Japan: Asia-Pacific Insulin Market Breakdown, by Type

8.1.1.4 Australia: Asia-Pacific Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.1.1.4.1 Australia: Asia-Pacific Insulin Market Breakdown, by Type

8.1.1.5 Rest of Asia-Pacific : Asia-Pacific Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.1.1.5.1 Rest of Asia-Pacific : Asia-Pacific Insulin Market Breakdown, by Type

9. Competitive Landscape

9.1 Heat Map Analysis

9.2 Company Positioning and Concentration

10. Asia-Pacific Insulin Market Industry Landscape

10.1 Overview

10.2 Mergers and Acquisitions

10.3 Agreements, Collaborations, and Joint Ventures

10.4 New Product Launches

10.5 Expansions and Other Strategic Developments

11. Company Profiles

11.1 Adocia

11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments

11.2 Biocon

11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments

11.3 Eli Lilly and Company

11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments

11.4 GlaxoSmithKline plc.

11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments

11.5 Merck & Co., Inc.

11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments

11.6 Novo Nordisk A/S

11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments

11.7 Pfizer Inc.

11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments

11.8 Sanofi

11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments

11.9 Tonghua Dongbao Pharmaceutical Co., Ltd.

11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments

11.10 Wockhardt

11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments

12. Appendix

12.1 About Business Market Insights